

Title	Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331288 participants
Author(s)	NCD Risk Factor Collaboration (NCD-RisC); Walton, Janette
Publication date	2015-06-22
Original citation	Collaboration, N. C. D. R. F. (2015) 'Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331288 participants', The Lancet Diabetes & Endocrinology, 3(8), pp. 624-637. doi:10.1016/S2213-8587(15)00129-1
Type of publication	Article (peer-reviewed)
Link to publisher's version	http://dx.doi.org/10.1016/S2213-8587(15)00129-1 Access to the full text of the published version may require a subscription.
Rights	© NCD Risk Factor Collaboration. Open Access article distributed under the terms of CC BY. https://creativecommons.org/licenses/by/3.0/
Item downloaded from	http://hdl.handle.net/10468/3723

Downloaded on 2019-01-22T03:16:26Z



UCC

University College Cork, Ireland
 Coláiste na hOllscoile Corcaigh

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: NCD Risk Factor Collaboration (NCD-RisC). Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288 participants. *Lancet Diabetes Endocrinol* 2015; published online June 22. [http://dx.doi.org/10.1016/S2213-8587\(15\)00129-1](http://dx.doi.org/10.1016/S2213-8587(15)00129-1).

Webmaterials

Table of Contents

Webtable 1: Population-based surveys with individual-level data	1
Webtable 2: Population-based surveys with summarised prevalence data	6
Webfigure 1: Regional random effects in the regression of diabetes prevalence defined based on HbA _{1c} (HbA _{1c} ≥ 6.5% or history of diabetes or using insulin or oral hypoglycaemic agents) against diabetes prevalence defined based on FPG (FPG ≥ 7.0 mmol/L or history of diabetes or using insulin or oral hypoglycaemic agents)	9
Webfigure 2: Random effect meta-analysis of diabetes diagnostic sensitivity of HbA _{1c} ≥ 6.5% vs. FPG ≥ 7.0 mmol/L in previously-undiagnosed participants	11
Webfigure 3: Random effect meta-analysis of diabetes diagnostic specificity of HbA _{1c} ≥ 6.5% vs. FPG ≥ 7.0 mmol/L in previously-undiagnosed participants	13
Webfigure 4: Random effect meta-analysis of diabetes diagnostic sensitivity of HbA _{1c} ≥ 6.5% vs. 2hOGTT ≥ 11.1 mmol/L in previously-undiagnosed participants	15
Webfigure 5: Random effect meta-analysis of diabetes diagnostic specificity of HbA _{1c} ≥ 6.5% vs. 2hOGTT ≥ 11.1 mmol/L in previously-undiagnosed participants	17
Webfigure 6: Random effect meta-analysis of diabetes diagnostic sensitivity of HbA _{1c} ≥ 6.5% vs. FPG ≥ 7.0 mmol/L or 2hOGTT ≥ 11.1 mmol/L in previously-undiagnosed participants	19
Webfigure 7: Random effect meta-analysis of diabetes diagnostic specificity of HbA _{1c} ≥ 6.5% vs. FPG ≥ 7.0 mmol/L or 2hOGTT ≥ 11.1 mmol/L in previously-undiagnosed participants	21
Webfigure 8: Random effect meta-analysis of diabetes diagnostic sensitivity of FPG ≥ 7.0 mmol/L vs. 2hOGTT ≥ 11.1 mmol/L in previously-undiagnosed participants	23
Webfigure 9: Random effect meta-analysis of diabetes diagnostic specificity of FPG ≥ 7.0 mmol/L vs. 2hOGTT ≥ 11.1 mmol/L in previously-undiagnosed participants	25
References	27

Webtable 1: Population-based surveys with individual-level data

Survey name or citation	Country	Survey year(s)	Participants ≥ 18 years	Mean age (SD)	% Male	Level of representativeness	Rural, urban or both	Biomarkers available	Glucose measurement	HbA _{1c} measurement
Australian Diabetes Obesity and Lifestyle Study (AusDiab)	Australia	1999-2000	11,173	51.6 (14.4)	45.1%	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
Australian Diabetes Obesity and Lifestyle Study (AusDiab)	Australia	2004-2005	6,297	56.5 (12.7)	45.3%	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
Australian Diabetes Obesity and Lifestyle Study (AusDiab)	Australia	2011-2012	4,481	60.9 (11.2)	44.7%	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
North West Adelaide Health Study (NWAHS)	Australia	1999-2003	3,979	50.5 (16.4)	47.5%	Community	Urban	FPG, HbA _{1c}	Lab	Lab
North West Adelaide Health Study (NWAHS)	Australia	2004-2006	3,163	55.1 (15.5)	47.4%	Community	Urban	FPG, HbA _{1c}	Lab	Lab
North West Adelaide Health Study (NWAHS)	Australia	2008-2010	2,420	57.9 (14.3)	47.1%	Community	Urban	FPG, HbA _{1c}	Lab	Lab
The Central America Diabetes Initiative (CAMDI) Survey	Belize	2004-2005	1,306	45.7 (17.4)	38.9%	National	Both	FPG, 2hOGTT	Lab	-
Baependi Heart Study	Brazil	2010-2013	1,233	44.6 (16.5)	40.6%	Community	Rural	FPG, HbA _{1c}	Lab	Lab
China Health and Nutrition Study (CHNS)	China	2009	8,496	50.5 (15.0)	47.0%	National	Both	FPG, HbA _{1c}	Lab	Lab
Hong Kong Cardiovascular Risk Factor Prevalence Study	China (Hong Kong SAR)	1995-1996	2,762	45.9 (12.9)	49.2%	National	Both	FPG, 2hOGTT	Lab	-
The Central America Diabetes Initiative (CAMDI) Survey	Costa Rica	2004	974	45.3 (17.1)	32.9%	Community	Urban	FPG, 2hOGTT	Lab	-
Costa Rican Longevity and Healthy Aging Study (CRELES), Pre-1945 Cohort Wave 1	Costa Rica	2004-2006	2,587	76.2 (10.2)	45.3%	National	Both	FPG, HbA _{1c}	Lab	Lab
Costa Rican Longevity and Healthy Aging Study (CRELES), Pre-1945 Cohort Wave 2	Costa Rica	2006-2008	2,218	77.0 (9.6)	45.5%	National	Both	FPG, HbA _{1c}	Lab	Lab
Young Finns Study (YFS), Rural	Finland	2011	786	42.0 (4.9)	46.3%	National	rural	FPG, HbA _{1c}	Lab	Lab
Young Finns Study (YFS), Urban	Finland	2011	1,121	41.9 (5.1)	44.2%	National	Urban	FPG, HbA _{1c}	Lab	Lab
The Three City Study (3C Study)	France	2008-2010	693	82.3 (4.4)	36.1%	Community	Urban	FPG, HbA _{1c}	Lab	Lab
Population Health Survey in Greenland	Greenland	2005-2010	3,046	44.5 (14.7)	43.9%	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
The Central America Diabetes Initiative (CAMDI) Survey	Guatemala	2001-2002	848	40.5 (15.4)	33.6%	Community	Urban	FPG, 2hOGTT	Lab	-
The Central America Diabetes Initiative (CAMDI) Survey	Honduras	2003-2004	1,179	40.6 (15.6)	35.5%	Community	Urban	FPG, 2hOGTT	Lab	-
New Delhi Birth Cohort, Follow-up Phase 1	India	1999-2002	1,434	28.7 (1.4)	59.0%	Community	Urban	FPG, 2hOGTT	Lab	-
New Delhi Birth Cohort, Follow-up Phase 2	India	2006-2009	1,075	35.6 (1.1)	59.5%	Community	Urban	FPG, 2hOGTT	Lab	-
Chennai Urban Rural Epidemiology Study (CURES)	India	2001-2004	2,349	39.6 (12.9)	46.7%	Community	Urban	FPG, 2hOGTT, HbA _{1c}	Lab	Lab

Survey name or citation	Country	Survey year(s)	Participants ≥ 18 years	Mean age (SD)	% Male	Level of representativeness	Rural, urban or both	Biomarkers available	Glucose measurement	HbA _{1c} measurement
High Prevalence of Diabetes and Cardiovascular Risk Factors Associated with Urbanization in India. Diabetes Care. 2008;31:893-8.	India	2006	7,057	38.0 (12.1)	47.0%	Community	Both	FPG, 2hOGTT	Lab	-
Bruneck Study	Italy	1990	908	58.8 (11.4)	51.1%	Community	Rural	FPG, 2hOGTT	Lab	-
Bruneck Study	Italy	1995	775	62.6 (11.1)	50.6%	Community	Rural	FPG, 2hOGTT	Lab	-
Bruneck Study	Italy	2000	692	66.0 (10.3)	47.8%	Community	Rural	FPG, HbA _{1c}	Lab	Lab
Bruneck Study	Italy	2005	568	69.1 (9.5)	46.3%	Community	Rural	FPG, HbA _{1c}	Lab	Lab
Bruneck Study	Italy	2010	484	72.5 (8.5)	46.5%	Community	Rural	FPG, HbA _{1c}	Lab	Lab
Epidemiological Survey of Kiribati, Rural	Kiribati	1981	970	41.7 (15.8)	47.3%	Subnational	Rural	FPG, 2hOGTT	Lab	-
Epidemiological Survey of Kiribati, Urban	Kiribati	1981	1,720	35.9 (12.4)	50.6%	Subnational	Urban	FPG, 2hOGTT	Lab	-
Metabolic Syndrome Study in Malaysia	Malaysia	2008	4,091	48.1 (14.5)	34.9%	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
Mauritius Noncommunicable Disease Survey	Mauritius	1987	4,960	43.4 (13.2)	46.9%	National	Both	FPG, 2hOGTT	Lab	-
Mauritius Noncommunicable Disease Survey	Mauritius	1992	6,453	45.6 (12.1)	46.2%	National	Both	FPG, 2hOGTT	Lab	-
Mauritius Noncommunicable Disease Survey	Mauritius	1998	5,355	48.9 (11.4)	44.3%	National	Both	FPG, 2hOGTT	Lab	-
Mauritius Noncommunicable Disease Survey	Mauritius	2009	6,080	45.9 (13.6)	45.7%	National	Both	FPG, 2hOGTT	Lab	-
Trends in the Prevalence and Incidence of Non-insulin-dependent Diabetes Mellitus and Impaired Glucose Tolerance	Nauru	1975-1976	425	36.1 (13.5)	48.5%	Subnational	Both	FPG, 2hOGTT	Lab	-
Trends in the Prevalence and Incidence of Non-insulin-dependent Diabetes Mellitus and Impaired Glucose Tolerance	Nauru	1982	1,393	36.5 (13.4)	47.5%	National	Both	FPG, 2hOGTT	unknown	-
Trends in the Prevalence and Incidence of Non-insulin-dependent Diabetes Mellitus and Impaired Glucose Tolerance	Nauru	1987	1,072	39.3 (12.8)	45.3%	National	Both	FPG, 2hOGTT	Lab	-
Trends in the Prevalence and Incidence of Non-insulin-dependent Diabetes Mellitus and Impaired Glucose Tolerance	Nauru	1994	1,364	39.0 (11.3)	47.1%	National	Both	FPG, 2hOGTT	Lab	-
The Central America Diabetes Initiative (CAMDI) Survey	Nicaragua	2003-2004	1,552	40.2 (14.8)	46.0%	Community	Urban	FPG, 2hOGTT	Lab	-
Survey in Ramallah District, Rural *	Occupied Palestinian Territory	1996-1998	606	37.9 (12.7)	33.5%	Community	Rural	FPG, 2hOGTT	Portable for FPG Lab for 2hOGTT	-
Survey in Ramallah District, Urban *	Occupied Palestinian Territory	1996-1998	637	38.6 (12.7)	28.6%	Community	Urban	FPG, 2hOGTT	Portable for FPG Lab for 2hOGTT	-

Survey name or citation	Country	Survey year(s)	Participants ≥ 18 years	Mean age (SD)	% Male	Level of representativeness	Rural, urban or both	Biomarkers available	Glucose measurement	HbA _{1c} measurement
Peru Migrant Study	Peru	2007-2008	848	50.6 (10.9)	48.0%	Community	Both	FPG, HbA _{1c}	Lab	Lab
CRONICAS Cohort Study	Peru	2009-2012	3,114	55.2 (12.7)	48.7%	Subnational	Both	FPG, HbA _{1c}	Lab	Lab
Seychelles Heart Survey IV	Seychelles	2014	1,212	45.8 (11.1)	43.4%	National	Both	FPG, HbA _{1c}	Lab	Lab
Cape Town Bellville South Cohort Study, Baseline Evaluation I	South Africa	2008-2009	924	54.3 (14.7)	23.6%	Community	Urban	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
Korea National Health and Nutrition Examination Survey	South Korea	2011	5,715	50.2 (16.6)	43.0%	National	Both	FPG, HbA _{1c}	Lab	Lab
Korea National Health and Nutrition Examination Survey	South Korea	2012	5,237	50.5 (16.6)	42.1%	National	Both	FPG, HbA _{1c}	Lab	Lab
Harmonizing Equation of Risk in Mediterranean countries Extremadura (The HERMEX study)	Spain	2007-2009	2,787	50.8 (14.4)	46.5%	Subnational	Both	FPG, HbA _{1c}	Lab	Lab
Study on Nutrition and Cardiovascular Risk in Spain	Spain	2008-2010	12,821	47.2 (16.7)	47.4%	National	Both	FPG, HbA _{1c}	Lab	Lab
Turkish Adult Risk Factor Study	Turkey	2012-2013	425	58.3 (10.1)	48.5%	National	Both	FPG, HbA _{1c}	Portable	Lab
The Funafuti Survey	Tuvalu	1976	415	38.2 (15.5)	49.4%	Subnational	Both	FPG, 2hOGTT	Lab	-
Hertfordshire Cohort Study	UK	1999-2004	2,758	65.7 (2.9)	52.5%	Subnational	Both	FPG, 2hOGTT	Lab	-
Health Survey for England	UK	2003	1,096	57.2 (14.0)	47.8%	National	Both	FPG, HbA _{1c}	Lab	Lab
English Longitudinal Study of Ageing, Wave 2	UK	2004-2005	3,701	63.8 (7.4)	46.5%	National	Both	FPG, HbA _{1c}	Lab	Lab
English Longitudinal Study of Ageing, Wave 4	UK	2008-2009	4,008	64.1 (7.5)	46.1%	National	Both	FPG, HbA _{1c}	Lab	Lab
English Longitudinal Study of Ageing, Wave 6	UK	2012-2013	3,465	65.8 (7.6)	44.0%	National	Both	FPG, HbA _{1c}	Lab	Lab
MRC National Survey of Health and Development (NSHD)	UK	2009	1,758	62.0 (0.0)	47.6%	National	Both	FPG, HbA _{1c}	Lab	Lab
United States National Health and Nutrition Examination Survey (US NHANES)	USA	1976-1980	3,808	48.8 (16.7)	47.2%	National	Both	FPG, 2hOGTT	Lab	-
United States National Health and Nutrition Examination Survey (US NHANES)	USA	1988-1994	3,310	56.7 (11.2)	48.7%	National	Both	FPG, 2hOGTT	Lab	-
United States National Health and Nutrition Examination Survey (US NHANES)	USA	1999-2000	1,943	47.6 (19.8)	50.0%	National	Both	FPG, HbA _{1c}	Lab	Lab
United States National Health and Nutrition Examination Survey (US NHANES)	USA	2001-2002	2,305	47.2 (20.0)	51.1%	National	Both	FPG, HbA _{1c}	Lab	Lab
United States National Health and Nutrition Examination Survey (US NHANES)	USA	2003-2004	2,111	47.9 (20.8)	50.6%	National	Both	FPG, HbA _{1c}	Lab	Lab
United States National Health and Nutrition Examination Survey (US NHANES)	USA	2005-2006	2,057	46.6 (20.1)	52.6%	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab

Survey name or citation	Country	Survey year(s)	Participants ≥ 18 years	Mean age (SD)	% Male	Level of representativeness	Rural, urban or both	Biomarkers available	Glucose measurement	HbA_{1c} measurement
United States National Health and Nutrition Examination Survey (US NHANES)	USA	2007-2008	2,450	49.5 (18.5)	49.7%	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
United States National Health and Nutrition Examination Survey (US NHANES)	USA	2009-2010	2,732	48.2 (18.5)	47.4%	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
United States National Health and Nutrition Examination Survey (US NHANES)	USA	2011-2012	2,409	47.3 (18.2)	50.4%	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab


*Fasting glucose was measured in capillary whole blood, and was converted to plasma-equivalent by multiplying by 1.11.¹

Webtable 2: Population-based surveys with summarised prevalence data


Survey name	Country	Survey year(s)	Participants ≥ 18 years	Level of representative- ness	Rural, urban or both	Biomarkers available	Glucose measurement	HbA _{1c} measurement
China Noncommunicable Disease Survey	China	2010-2011	97,630	National	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
Nutrition and Health of Aging Population in China	China	2011	2,241	Community	Both	FPG, HbA _{1c}	Lab	Lab
Kuopio Ischaemic Heart Disease Risk factor Study	Finland	1991-1993	517	National	Both	FPG, 2hOGTT	Lab	-
Kuopio Ischaemic Heart Disease Risk factor Study	Finland	1998-2001	1,135	National	Both	FPG, 2hOGTT	Lab	-
Kuopio Ischaemic Heart Disease Risk factor Study	Finland	2005-2008	1,703	National	Both	FPG, 2hOGTT	Lab	-
National Monitoring of Arterial Risk (MONA LISA) in Lille	France	2004-2006	1,378	Community	Urban	FPG, HbA _{1c}	Lab	Lab
National Monitoring of Arterial Risk (MONA LISA) in Bas-Rhin	France	2005-2007	1,459	Subnational	Both	FPG, HbA _{1c}	Lab	Lab
Etude Nationale Nutrition Sante	France	2006-2007	1,936	National	Both	FPG, HbA _{1c}	Lab	Lab
Enquête Littorale Souffle Air Biologie Environnement (ELISABET) Dunkerque	France	2011-2013	786	Community	Urban	FPG, HbA _{1c}	Lab	Lab
Enquête Littorale Souffle Air Biologie Environnement (ELISABET) Lille	France	2011-2013	1,322	Community	Urban	FPG, HbA _{1c}	Lab	Lab
KORA S4 Study: Kooperative Research in the Region of Augsburg Survey 4	Germany	1999-2001	1,641	Subnational	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
KORA F4 Study: Kooperative Research in the Region of Augsburg Follow-Up of Survey 4	Germany	2006-2008	2,829	Subnational	Both	FPG, 2hOGTT, HbA _{1c}	Lab	Lab
German Health Interview and Examination Survey for Adults 2008-2011 (DEGS1)	Germany	2008-2011	5,560	National	Both	FPG, HbA _{1c}	Lab	Lab
Chennai Urban Population Study (CUPS)	India	1996-1999	310	Community	Urban	FPG, 2hOGTT	Lab	-
The Hisayama Study	Japan	2002-2003	3,212	Community	Rural	FPG, HbA _{1c}	Lab	Lab
National Health and Nutrition Survey	Japan	2005	1,360	National	Both	FPG, HbA _{1c}	Lab	Lab
National Health and Nutrition Survey	Japan	2006	1,520	National	Both	FPG, HbA _{1c}	Lab	Lab
National Health and Nutrition Survey	Japan	2007	1,413	National	Both	FPG, HbA _{1c}	Lab	Lab
National Health and Nutrition Survey	Japan	2008	1,618	National	Both	FPG, HbA _{1c}	Lab	Lab
National Health and Nutrition Survey	Japan	2009	1,668	National	Both	FPG, HbA _{1c}	Lab	Lab
National Health and Nutrition Survey	Japan	2010	1,430	National	Both	FPG, HbA _{1c}	Lab	Lab
Observation des Risques et de la Sante Cardio-Vasculaire au Luxembourg (ORISCAV-LUX)	Luxembourg	2007-2009	1,200	National	Both	FPG, HbA _{1c}	Lab	Lab
Healthy Life in an Urban Setting (HELIUS)	Netherlands	2011-2013	1,380	Community	Urban	FPG, HbA _{1c}	Lab	Lab

Survey name	Country	Survey year(s)	Participants ≥ 18 years	Level of representative- ness	Rural, urban or both	Biomarkers available	Glucose measurement	HbA_{1c} measurement
Life Course Study in Cardiovascular Disease Epidemiology	Philippines	2009	623	Subnational	Both	FPG, 2hOGTT	Lab	-
Study of prevalence and control of CVD risk factors in the general adult population in Poland (NATPOL)	Poland	2011	535	National	Both	FPG, HbA _{1c}	Lab	Lab
Singapore Health Study 2012	Singapore	2012-2013	1,712	National	Both	FPG, HbA _{1c}	Lab	Lab
Taiwanese Survey on Hypertension, Hyperglycemia and Hyperlipidemia	Taiwan	2002	6,015	National	Both	FPG, HbA _{1c}	Lab	Lab
Taiwanese Survey on Hypertension, Hyperglycemia and Hyperlipidemia	Taiwan	2007	4,023	National	Both	FPG, HbA _{1c}	Lab	Lab
Edinburgh Artery Study	UK	1987-1988	342	Community	Urban	FPG, 2hOGTT	Lab	-

Webfigure 1: Regional random effects in the regression of diabetes prevalence defined based on HbA_{1c} (HbA_{1c} \geq 6.5% or history of diabetes or using insulin or oral hypoglycaemic agents) against diabetes prevalence defined based on FPG (FPG \geq 7.0 mmol/L or history of diabetes or using insulin or oral hypoglycaemic agents)




Webfigure 2: Random effect meta-analysis of diabetes diagnostic sensitivity of $\text{HbA}_{1c} \geq 6.5\%$ vs. $\text{FPG} \geq 7.0$ mmol/L in previously-undiagnosed participants



Webfigure 3: Random effect meta-analysis of diabetes diagnostic specificity of $\text{HbA}_{1c} \geq 6.5\%$ vs. $\text{FPG} \geq 7.0$ mmol/L in previously-undiagnosed participants

study_name	country	study_years	Specificity (95% CI)	Weight
Seychelles Heart Survey	Seychelles	2013-2014	88.13 (86.16, 90.11)	0.03
The Three city Study	France	2008-2010	90.86 (88.56, 93.17)	0.02
Chennai Urban Rural Epidemiology Study	India	2001-2004	92.30 (91.15, 93.46)	0.09
Baependi Heart Study	Brazil	2010-2013	94.09 (92.85, 95.33)	0.08
CRONICAS Cohort Study	Peru	2009-2012	94.57 (93.74, 95.40)	0.17
Cape Town Bellville South Cohort Study - Baseline evaluation I	South Africa	2008-2009	94.57 (92.89, 96.25)	0.04
China Health and Nutrition Study 2009	China	2009-2009	96.74 (96.35, 97.13)	0.76
Metabolic Syndrome Study in Malaysia	Malaysia	2008-2008	96.98 (96.40, 97.56)	0.35
North West Adelaide Health Study	Australia	1999-2003	97.07 (96.53, 97.61)	0.41
Bruneck Study	Italy	2000-2000	97.23 (95.93, 98.53)	0.07
Korea National Health and Nutrition Examination Survey	Republic of Korea	2012-2012	97.62 (97.19, 98.04)	0.64
Korea National Health and Nutrition Examination Survey	Republic of Korea	2011-2011	97.97 (97.59, 98.35)	0.80
Population Health Survey in Greenland	Greenland	2005-2010	97.98 (97.46, 98.50)	0.44
MRC National Survey of Health and Development	United Kingdom	2006-2011	98.33 (97.72, 98.93)	0.32
US NHANES 2011-2012	United States of America	2011-2012	98.41 (97.86, 98.95)	0.39
Costa Rican Longevity and Healthy Aging Study Pre-1945 Cohort Wave 1	Costa Rica	2004-2006	98.44 (97.89, 98.99)	0.38
English Longitudinal Study of Ageing Wave 2 2004-2005	United Kingdom	2004-2005	98.91 (98.55, 99.26)	0.93
US NHANES 2007-2008	United States of America	2007-2008	98.92 (98.47, 99.37)	0.58
US NHANES 2009-2010	United States of America	2009-2010	99.05 (98.65, 99.44)	0.75
Health Survey for England 2003	United Kingdom	2003-2003	99.23 (98.62, 99.84)	0.32
US NHANES 2001-2002	United States of America	2001-2002	99.27 (98.90, 99.64)	0.87
US NHANES 2003-2004	United States of America	2003-2004	99.41 (99.07, 99.76)	0.99
US NHANES 2005-2006	United States of America	2005-2006	99.50 (99.17, 99.83)	1.10
US NHANES 1999-2000	United States of America	1999-2000	99.72 (99.48, 99.97)	1.96
Harmonizing Equation of Risk in Mediterranean countries EXtremadura	Spain	2007-2009	99.87 (99.73, 100.02)	5.86
Study on Nutrition and Cardiovascular Risk in Spain	Spain	2008-2010	99.91 (99.86, 99.97)	41.01
The Australian Diabetes Obesity and Lifestyle Study 1999-2000	Australia	1999-2000	99.92 (99.87, 99.98)	40.65
Overall (I-squared = 98.2%, p = 0.000)			99.74 (99.71, 99.78)	100.00


Webfigure 4: Random effect meta-analysis of diabetes diagnostic sensitivity of $\text{HbA}_{1c} \geq 6.5\%$ vs. $2\text{hOGTT} \geq 11.1$ mmol/L in previously-undiagnosed participants



Webfigure 5: Random effect meta-analysis of diabetes diagnostic specificity of $\text{HbA}_{1c} \geq 6.5\%$ vs. $2\text{hOGTT} \geq 11.1$ mmol/L in previously-undiagnosed participants




Webfigure 6: Random effect meta-analysis of diabetes diagnostic sensitivity of $\text{HbA}_{1c} \geq 6.5\%$ vs. $\text{FPG} \geq 7.0$ mmol/L or $2\text{hOGTT} \geq 11.1$ mmol/L in previously-undiagnosed participants



Webfigure 7: Random effect meta-analysis of diabetes diagnostic specificity of $\text{HbA}_{1c} \geq 6.5\%$ vs. $\text{FPG} \geq 7.0$ mmol/L or $2\text{hOGTT} \geq 11.1$ mmol/L in previously-undiagnosed participants



Webfigure 8: Random effect meta-analysis of diabetes diagnostic sensitivity of FPG ≥ 7.0 mmol/L vs. 2hOGTT ≥ 11.1 mmol/L in previously-undiagnosed participants



Webfigure 9: Random effect meta-analysis of diabetes diagnostic specificity of FPG ≥ 7.0 mmol/L vs. 2hOGTT ≥ 11.1 mmol/L in previously-undiagnosed participants

study_name	country	study_years	Specificity (95% CI)	% Weight
Trends in the prevalence and incidence of non-insulin-dependent diabetes mellitus and impaired glucose tolerance	Nauru	1994-1994	92.73 (91.10, 94.35)	0.20
Cape Town Bellville South Cohort Study - Baseline evaluation I	South Africa	2008-2009	93.30 (91.46, 95.13)	0.16
Trends in the prevalence and incidence of non-insulin-dependent diabetes mellitus and impaired glucose tolerance	Nauru	1987-1987	93.32 (91.59, 95.06)	0.18
Population Health Survey in Greenland	Greenland	2005-2010	96.51 (95.82, 97.20)	1.12
Hertfordshire Cohort Study	United Kingdom	1999-2004	96.66 (95.96, 97.36)	1.07
Metabolic Syndrome Study in Malaysia	Malaysia	2008-2008	96.66 (96.04, 97.29)	1.35
Mauritius non communicable diseases survey	Mauritius	2009-2009	96.92 (96.42, 97.41)	2.16
Trends in the prevalence and incidence of non-insulin-dependent diabetes mellitus and impaired glucose tolerance	Nauru	1982-1982	97.16 (96.15, 98.16)	0.52
New Delhi Birth Cohort	India	1999-2002	97.16 (96.29, 98.03)	0.70
Mauritius non communicable disease survey	Mauritius	1992-1992	97.47 (97.05, 97.89)	2.97
Mauritius non communicable disease survey	Mauritius	1998-1998	98.08 (97.66, 98.50)	2.99
US NHANES 2009-2010	United States of America	2009-2010	98.08 (97.48, 98.68)	1.48
Epidemiological survey of Kiribati	Kiribati	1981-1981	98.11 (97.44, 98.78)	1.17
US NHANES 2007-2008	United States of America	2007-2008	98.15 (97.52, 98.77)	1.34
Survey in Ramallah District Urban	Occupied Palestinian Territory	1996-1998	98.44 (97.43, 99.45)	0.52
CAMDI	Belize	2004-2005	98.46 (97.77, 99.15)	1.12
Mauritius non communicable disease survey	Mauritius	1987-1987	98.56 (98.20, 98.92)	4.17
US NHANES 2011-2012	United States of America	2011-2012	98.82 (98.31, 99.32)	2.08
CAMDI	Costa Rica	2004-2004	98.83 (98.15, 99.52)	1.13
US NHANES III	United States of America	1988-1994	98.87 (98.57, 99.17)	5.97
The Australian Diabetes Obesity and Lifestyle Study 1999-2000	Australia	1999-2000	98.92 (98.72, 99.13)	13.09
CAMDI	Honduras	2003-2004	99.03 (98.46, 99.60)	1.62
US NHANES II	United States of America	1976-1980	99.12 (98.81, 99.43)	5.54
Bruneck Study	Italy	1990-1990	99.16 (98.54, 99.78)	1.37
The Funafuti Survey	Tuvalu	1976-1976	99.25 (98.40, 100.10)	0.74
US NHANES 2005-2006	United States of America	2005-2006	99.31 (98.90, 99.72)	3.17
CAMDI	Nicaragua	2003-2004	99.40 (99.00, 99.79)	3.41
Hong Kong Cardiovascular Risk Factor Prevalence Study 1995-1996	China (Hong Kong SAR)	1995-1996	99.40 (99.10, 99.70)	5.75
High prevalence of diabetes and CVD risk factors associated with urbanization in India. Diabetes Care 2008	India	2006-2006	99.42 (99.23, 99.61)	14.72
CAMDI	Guatemala	2001-2002	99.50 (99.01, 99.99)	2.19
Epidemiological survey of Kiribati	Kiribati	1981-1981	99.57 (99.16, 99.99)	3.05
Survey in Ramallah District Rural	Occupied Palestinian Territory	1996-1998	99.64 (99.15, 100.14)	2.15
Chennai Urban Rural Epidemiology Study	India	2001-2004	99.75 (99.53, 99.97)	10.83
Overall (I-squared = 94.4%, p = 0.000)			98.90 (98.83, 98.97)	100.00

References

1. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Clin Chem* 2011; **57**(6): e1-e47.